Skip to content
Clinical Trials – home
Therapeutic area

Psychiatric disorders – page 30

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Ketamine Infusion Study for Symptom Improvement in Patients with Severe Borderline Personality Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Study on Donanemab, Florbetapir, and Flortaucipir for Patients with Early Alzheimer's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Donanemab
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Semaglutide in Patients with Early Alzheimer's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on the Effects of GV1001 for Patients with Mild to Moderate Alzheimer's Disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Tertomotide
  • Sponsor:Gemvax & Kael Co. Ltd.

Study on the Effectiveness and Safety of AVP-786 (Quinidine Sulfate and Deudextromethorphan Hydrobromide) for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Iclepertin
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Masupirdine for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Masupirdine
  • Sponsor:Suven Life Sciences Limited

Insomnia

Not recruiting

Study on the Effects of Tasipimidine for Patients with Insomnia Disorder

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Tasipimidine
  • Sponsor:Orion Corporation

Narcolepsy

Not recruiting

Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Eisai Limited

Delirium

Not recruiting

Study of intranasal insulin to prevent delirium in patients aged 65 years or older following elective cardiac surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Insulin Human
  • Sponsor:Stichting Radboud University Medical Center

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.